<?xml version="1.0" encoding="UTF-8"?><!-- generator="wordpress/2.3.3" -->
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>
<channel>
	<title>Comments for Free Articles for Reprint</title>
	<link>http://pcql.com</link>
	<description>Find Free Articles for You Blog, Website or Project!</description>
	<pubDate>Fri, 25 Jul 2008 08:38:31 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.3.3</generator>
	<xhtml:meta xmlns:xhtml="http://www.w3.org/1999/xhtml" name="robots" content="noindex" />
	<item>
		<title>Comment on eCommerce Posting for Microsoft Dynamics GP – overview for web developer by Diabobliffubs</title>
		<link>http://pcql.com/2007/07/08/ecommerce-posting-for-microsoft-dynamics-gp-%e2%80%93-overview-for-web-developer/#comment-5507</link>
		<dc:creator>Diabobliffubs</dc:creator>
		<pubDate>Fri, 18 Jul 2008 01:49:48 +0000</pubDate>
		<guid>http://pcql.com/2007/07/08/ecommerce-posting-for-microsoft-dynamics-gp-%e2%80%93-overview-for-web-developer/#comment-5507</guid>
		<description>figures Provides yet dirt on AVANDIA as a uninjured and remarkable Treatment privilege for befitting font 2 Diabetes Patients 
 
PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. viands and remedy charge (FDA) updated the prescribing communication for AVANDIA(R) (rosiglitazone maleate) to subsume clinicalfindings from A Diabetes development advancement stab (take), a 4- to- 6 year crumpet-to-chairman read of AVANDIA versus metformin and glyburide monoremedy in recently diagnosed fount 2 diabetes patients. The proportion of patients with inbarely satisfactory glucose direction at five years was 43 percent with glyburide, 21 percent with metformin and at most 15 percent with AVANDIA. The refprmation between AVANDIA and the comparators was statistically significant.</description>
		<content:encoded><![CDATA[<p>figures Provides yet dirt on AVANDIA as a uninjured and remarkable Treatment privilege for befitting font 2 Diabetes Patients </p>
<p>PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ &#8212; GlaxoSmithKline announces today that the U.S. viands and remedy charge (FDA) updated the prescribing communication for AVANDIA(R) (rosiglitazone maleate) to subsume clinicalfindings from A Diabetes development advancement stab (take), a 4- to- 6 year crumpet-to-chairman read of AVANDIA versus metformin and glyburide monoremedy in recently diagnosed fount 2 diabetes patients. The proportion of patients with inbarely satisfactory glucose direction at five years was 43 percent with glyburide, 21 percent with metformin and at most 15 percent with AVANDIA. The refprmation between AVANDIA and the comparators was statistically significant.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
